Teniposide in the treatment of leukemia: A case study of conflicting priorities in the development of drugs for fatal diseases

J. L. Grem, D. F. Hoth, B. Leyland-Jones, S. A. King, R. S. Ungerleider, R. E. Wittes

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Teniposide, a semisynthetic epipodophyllotoxin, was found to be highly active against murine leukemias, and the combination of teniposide with cytosine arabinoside (ara-C) was curative in murine leukemia models. The antitumor activity in preclinical models prompted introduction of teniposide into the clinic in 1971. Although teniposide as a single agent rarely produced a complete remission in heavily pretreated leukemia patients, teniposide plus ara-C produced complete remissions in some patients with refractory and relapsed acute lymphoblastic leukemia (ALL). Innovative front-line and salvage regimens using teniposide have been developed that incorporate a multi-drug strategy with early intensification, rotation of drug combinations in maintenance, and regional therapy in an effort to improve the cure rate in leukemia. However, as the complexity of these regimens increases, the contribution of an individual component such as teniposide becomes less clear. Although some of these regimens for newly diagnosed and relapsed ALL are now thought to represent the best available therapy, teniposide remains an investigational agent. In this review, we outline and discuss the conflicts arising from the need to answer drug-specific issues, and, at the same time, facilitate the implementation of innovation, curative regimens.

Original languageEnglish (US)
Pages (from-to)351-379
Number of pages29
JournalJournal of Clinical Oncology
Volume6
Issue number2
DOIs
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Teniposide
Leukemia
Pharmaceutical Preparations
Cytarabine
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Podophyllotoxin
Drug Combinations
Maintenance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Teniposide in the treatment of leukemia : A case study of conflicting priorities in the development of drugs for fatal diseases. / Grem, J. L.; Hoth, D. F.; Leyland-Jones, B.; King, S. A.; Ungerleider, R. S.; Wittes, R. E.

In: Journal of Clinical Oncology, Vol. 6, No. 2, 01.01.1988, p. 351-379.

Research output: Contribution to journalReview article

Grem, J. L. ; Hoth, D. F. ; Leyland-Jones, B. ; King, S. A. ; Ungerleider, R. S. ; Wittes, R. E. / Teniposide in the treatment of leukemia : A case study of conflicting priorities in the development of drugs for fatal diseases. In: Journal of Clinical Oncology. 1988 ; Vol. 6, No. 2. pp. 351-379.
@article{3ca31ca037974f69a300e627bcab5b7f,
title = "Teniposide in the treatment of leukemia: A case study of conflicting priorities in the development of drugs for fatal diseases",
abstract = "Teniposide, a semisynthetic epipodophyllotoxin, was found to be highly active against murine leukemias, and the combination of teniposide with cytosine arabinoside (ara-C) was curative in murine leukemia models. The antitumor activity in preclinical models prompted introduction of teniposide into the clinic in 1971. Although teniposide as a single agent rarely produced a complete remission in heavily pretreated leukemia patients, teniposide plus ara-C produced complete remissions in some patients with refractory and relapsed acute lymphoblastic leukemia (ALL). Innovative front-line and salvage regimens using teniposide have been developed that incorporate a multi-drug strategy with early intensification, rotation of drug combinations in maintenance, and regional therapy in an effort to improve the cure rate in leukemia. However, as the complexity of these regimens increases, the contribution of an individual component such as teniposide becomes less clear. Although some of these regimens for newly diagnosed and relapsed ALL are now thought to represent the best available therapy, teniposide remains an investigational agent. In this review, we outline and discuss the conflicts arising from the need to answer drug-specific issues, and, at the same time, facilitate the implementation of innovation, curative regimens.",
author = "Grem, {J. L.} and Hoth, {D. F.} and B. Leyland-Jones and King, {S. A.} and Ungerleider, {R. S.} and Wittes, {R. E.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1200/JCO.1988.6.2.351",
language = "English (US)",
volume = "6",
pages = "351--379",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Teniposide in the treatment of leukemia

T2 - A case study of conflicting priorities in the development of drugs for fatal diseases

AU - Grem, J. L.

AU - Hoth, D. F.

AU - Leyland-Jones, B.

AU - King, S. A.

AU - Ungerleider, R. S.

AU - Wittes, R. E.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Teniposide, a semisynthetic epipodophyllotoxin, was found to be highly active against murine leukemias, and the combination of teniposide with cytosine arabinoside (ara-C) was curative in murine leukemia models. The antitumor activity in preclinical models prompted introduction of teniposide into the clinic in 1971. Although teniposide as a single agent rarely produced a complete remission in heavily pretreated leukemia patients, teniposide plus ara-C produced complete remissions in some patients with refractory and relapsed acute lymphoblastic leukemia (ALL). Innovative front-line and salvage regimens using teniposide have been developed that incorporate a multi-drug strategy with early intensification, rotation of drug combinations in maintenance, and regional therapy in an effort to improve the cure rate in leukemia. However, as the complexity of these regimens increases, the contribution of an individual component such as teniposide becomes less clear. Although some of these regimens for newly diagnosed and relapsed ALL are now thought to represent the best available therapy, teniposide remains an investigational agent. In this review, we outline and discuss the conflicts arising from the need to answer drug-specific issues, and, at the same time, facilitate the implementation of innovation, curative regimens.

AB - Teniposide, a semisynthetic epipodophyllotoxin, was found to be highly active against murine leukemias, and the combination of teniposide with cytosine arabinoside (ara-C) was curative in murine leukemia models. The antitumor activity in preclinical models prompted introduction of teniposide into the clinic in 1971. Although teniposide as a single agent rarely produced a complete remission in heavily pretreated leukemia patients, teniposide plus ara-C produced complete remissions in some patients with refractory and relapsed acute lymphoblastic leukemia (ALL). Innovative front-line and salvage regimens using teniposide have been developed that incorporate a multi-drug strategy with early intensification, rotation of drug combinations in maintenance, and regional therapy in an effort to improve the cure rate in leukemia. However, as the complexity of these regimens increases, the contribution of an individual component such as teniposide becomes less clear. Although some of these regimens for newly diagnosed and relapsed ALL are now thought to represent the best available therapy, teniposide remains an investigational agent. In this review, we outline and discuss the conflicts arising from the need to answer drug-specific issues, and, at the same time, facilitate the implementation of innovation, curative regimens.

UR - http://www.scopus.com/inward/record.url?scp=0023836913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023836913&partnerID=8YFLogxK

U2 - 10.1200/JCO.1988.6.2.351

DO - 10.1200/JCO.1988.6.2.351

M3 - Review article

C2 - 3276827

AN - SCOPUS:0023836913

VL - 6

SP - 351

EP - 379

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -